Susan a Griffiths (28 results)

Paperback. Condition: Very Good. 10th. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.

Condition: good. Fast Free Shipping â" Good condition. It may show normal signs of use, such as light writing, highlighting, or library markings, but all pages are intact and the book is fully readable. A solid, complete copy that's ready to enjoy.

paperback. Condition: Good. Connecting readers with great books since 1972! Used textbooks may not include companion materials such as access codes, etc. May have some wear or writing/highlighting. We ship orders daily and Customer Service is our top priority.

Soft cover. Condition: Very Good. 1st Edition. 64 pages. (SL#31).

Condition: Very Good. Very Good Condition. Five star seller - Buy with confidence. Nurak, Roni (illustrator).

Condition: Good. Some light marks to the cover. The book is clean and readable throughout, a decent copy.

Soft cover. Condition: Very Good. 155 pages. Tibor Fischer "Fifty Uselessnesses) / Anthony Doerr "Only So Many Chances" / Richard Wagner "8 stories" / Linda A Fiore "Cherry Pie Red" / Matthew David Brozik "The Admirable Vice Provost" / Susan Neville "Copies" (SL#48).

Softcover. Condition: Near Fine. Vol. LXX, No. 1. Cover art by R. Crumb. Small quarto. 82pp. Stapled wrappers. Owner mailing label on cover, tiny crease at top corner of cover and several pages, else near fine. Includes "Grandparenting" by John Updike, "The Dark Music of the Rue du Cherche-Midi" by Muriel Spark. Also contributions from: A.R. Ammons, Roger Angell, Geroge Steiner, Paul Griffiths, Terrence Raffert, Nancy Franklin, John Lahr, Julian Barnes, Ever Meulen, Fredric Dannen, Susan Orlean, Andy Logan.…

Cloth/Laminated Boards. Condition: Like New. Dust Jacket Condition: No d/j as Published. Type: Book Considerable investment has been made by both pharmaceutical and biotechnology companies in pharmaceutical products of biotechnology. However, because relatively few of these products have been marketed, lack of relevant experience means that uncertainty still surrounds the most appropriate strategy for their safety evaluation. The 13th CMR International Workshop, held in February 1997, provided the opportunity for regulatory authority and industry experts from Europe, Japan and the USA to share their experiences of designing safety evaluation programmes for specific product classes: colony stimulating factors, growth factors, hormones, interferons, interleukins, monoclonal antibodies for therapeutic use, and gene therapy products. Participants worked together to recommend those studies that should be considered for such safety evaluation, and those that may be unnecessary. These recommendations subsequently made a valuable contribution to the ICH guideline "Safety Studies for Biotechnological Products", which was finalized at ICH 4 in Brussels in July 1997.200pp.…

Condition: New.

Condition: New. In English.

Condition: New. In English.

Condition: New.

Condition: New.

Condition: New. pp. 228.

Taschenbuch. Condition: Neu. Safety Evaluation of Biotechnologically-Derived Pharmaceuticals | Facilitating a Scientific Approach | Susan A Griffiths (u. a.) | Taschenbuch | Einband - flex.(Paperback) | Englisch | 2012 | Springer | EAN 9789401060431 | Verantwortliche Person für die EU: Springer Nature Customer Service Center GmbH, Haberstr. 7, 69126 Heidelberg, productsafety[at]springernature[dot]com | Anbieter: preigu.…

Gebunden. Condition: New. Considerable investment has been made by both pharmaceutical and biotechnology companies in pharmaceutical products of biotechnology. However, because relatively few of these products have been marketed, lack of relevant experience means that uncertainty.

Condition: New. Considerable investment has been made by both pharmaceutical and biotechnology companies in pharmaceutical products of biotechnology. However, because relatively few of these products have been marketed, lack of relevant experience means that uncertainty.

Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Considerable investment has been made by both pharmaceutical and biotechnology companies in pharmaceutical products of biotechnology. However, because relatively few of these products have been marketed, lack of relevant experience means that uncertainty still surrounds the most appropriate strategy for their safety evaluation. The 13th CMR International Workshop, held in February 1997, provided the opportunity for regulatory authority and industry experts from Europe, Japan and the USA to share their experiences of designing safety evaluation programmes for specific product classes: colony stimulating factors, growth factors, hormones, interferons, interleukins, monoclonal antibodies for therapeutic use, and gene therapy products. Participants worked together to recommend those studies that should be considered for such safety evaluation, and those that may be unnecessary. These recommendations subsequently made a valuable contribution to the ICH guideline `Safety Studies for Biotechnological Products', which was finalised at ICH 4 in Brussels in July 1997. The Workshop proceedings not only describe the recommendations but also provide the reader with an appreciation of the science behind safety evaluation strategies used by experts, the influence of different regulatory systems on these strategies, and the type of data required by both toxicologists and clinicians before they have sufficient confidence to administer pharmaceutical products of biotechnology to humans.…

Buch. Condition: Neu. Neuware - Considerable investment has been made by both pharmaceutical and biotechnology companies in pharmaceutical products of biotechnology. However, because relatively few of these products have been marketed, lack of relevant experience means that uncertainty still surrounds the most appropriate strategy for their safety evaluation. The 13th CMR International Workshop, held in February 1997, provided the opportunity for regulatory authority and industry experts from Europe, Japan and the USA to share their experiences of designing safety evaluation programmes for specific product classes: colony stimulating factors, growth factors, hormones, interferons, interleukins, monoclonal antibodies for therapeutic use, and gene therapy products. Participants worked together to recommend those studies that should be considered for such safety evaluation, and those that may be unnecessary. These recommendations subsequently made a valuable contribution to the ICH guideline `Safety Studies for Biotechnological Products', which was finalised at ICH 4 in Brussels in July 1997. The Workshop proceedings not only describe the recommendations but also provide the reader with an appreciation of the science behind safety evaluation strategies used by experts, the influence of different regulatory systems on these strategies, and the type of data required by both toxicologists and clinicians before they have sufficient confidence to administer pharmaceutical products of biotechnology to humans.…

Condition: As New. Unread book in perfect condition.

Hardcover. Condition: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Condition: As New. Unread book in perfect condition.

Paperback. Condition: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Taschenbuch. Condition: Neu. Cycles of Contingency | Developmental Systems and Evolution | Susan Oyama (u. a.) | Taschenbuch | Einband - flex.(Paperback) | Englisch | 2003 | MIT Press | EAN 9780262650632 | Verantwortliche Person für die EU: Libri GmbH, Europaallee 1, 36244 Bad Hersfeld, gpsr[at]libri[dot]de | Anbieter: preigu Print on Demand. …

Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Considerable investment has been made by both pharmaceutical and biotechnology companies in pharmaceutical products of biotechnology. However, because relatively few of these products have been marketed, lack of relevant experience means that uncertainty still surrounds the most appropriate strategy for their safety evaluation. The 13th CMR International Workshop, held in February 1997, provided the opportunity for regulatory authority and industry experts from Europe, Japan and the USA to share their experiences of designing safety evaluation programmes for specific product classes: colony stimulating factors, growth factors, hormones, interferons, interleukins, monoclonal antibodies for therapeutic use, and gene therapy products. Participants worked together to recommend those studies that should be considered for such safety evaluation, and those that may be unnecessary. These recommendations subsequently made a valuable contribution to the ICH guideline `Safety Studies for Biotechnological Products', which was finalised at ICH 4 in Brussels in July 1997. The Workshop proceedings not only describe the recommendations but also provide the reader with an appreciation of the science behind safety evaluation strategies used by experts, the influence of different regulatory systems on these strategies, and the type of data required by both toxicologists and clinicians before they have sufficient confidence to administer pharmaceutical products of biotechnology to humans. 224 pp. Englisch.…

Condition: New. Print on Demand pp. 228 52:B&W 6.14 x 9.21in or 234 x 156mm (Royal 8vo) Case Laminate on White w/Gloss Lam.

Condition: New. PRINT ON DEMAND pp. 228.